Correction to: Management of patients with chronic heart failure and type 2 diabetes mellitus: the SCODIAC-II study

Mariarosaria De Luca^{1,3} · Giorgio Bosso² · Antonio Valvano² · Vincenzo Guardasole^{1,3} · Amodio Botta³ · Vincenzo Carbone² · Giovanni Carella² · Andrea Del Buono³ · Giuseppe Di Giovanni³ · Biagio Fimiani² · Franco Guarnaccia² · Emanuela Lapice³ · Emilia Martedi³ · Giuseppe Memoli³ · Domenica Oliva³ · Geremia Romano³ · Antonio Cittadini¹ · Giovanni Battista Zito² · Ugo Oliviero^{1,2}

Published online: 29 September 2021
© Società Italiana di Medicina Interna (SIMI) 2021

Correction to: Internal and Emergency Medicine <https://doi.org/10.1007/s11739-020-02528-4>

In the original publication of the article, there is a DOI registration problem. Also the content of Para ID = "Par2", Para ID = "Par23", Para ID = "Par32" is wrong.

The correction is as follows,

<ClassificationGroup><CharacteristicValue Characteristic = "TrialID">NCT04375943</CharacteristicValue><CharacteristicValue Characteristic = "TrialRegistry">NCT</CharacteristicValue></ClassificationGroup>

<Para ID = "Par2"><Emphasis Type = "Bold">Trial registration</Emphasis>The protocol was approved by the University of Naples Federico II Ethics Committee and registered at ClinicalTrial.gov (NCT04375943). The principles outlined in the Declaration of Helsinki were followed.</Para>

<Para ID = "Par23">The protocol was approved by the University of Naples Federico II Ethics Committee and registered at ClinicalTrial.gov (NCT04375943). The principles outlined in the Declaration of Helsinki were followed. The 406 patients were divided in two groups according different values of left ventricular Ejection Fraction (EF): 136 HF diabetic patients with preserved EF (HF-pEF) (> 45%) were assigned to Group A and 270 HF diabetic patients with

reduced EF (HF-rEF) ($\leq 45\%$) to Group B. All patients had performed periodic evaluations by their own Cardiologists and Diabetologists and an echocardiographic examination at beginning and after 1 year of treatment. Clinical and laboratory parameters, disease duration, HF etiologies, co-morbidities and complications, number of accesses to the pertaining healthcare district and ongoing therapies were collected. The echocardiographic parameters recorded at the beginning and at the end of the study period were: LV (Left Ventricular) volume at end diastole and end systole, LV mass, relative wall thickness and left atrial volume, LV ejection fraction using Simpson's biplane rule, peak velocity of mitral E and A waves and the E/A ratio, Tissue Doppler Imaging (TDI) diastolic velocities of mitral annulus and the E/E' ratio. A comparison of the echocardiographic parameters registered at baseline and at the end of the study was performed between patients who assumed SGLT2i and patients who not assumed, for each EF group.</Para>

<Para ID = "Par32">The protocol was approved by the University of Naples Federico II Ethics Committee and registered at <Emphasis Type = "Italic">ClinicalTrial.gov</Emphasis> (NCT04375943). The principles outlined in the Declaration of Helsinki were followed.</Para>

The original article was corrected.

The original article can be found online at <https://doi.org/10.1007/s11739-020-02528-4>.

✉ Ugo Oliviero
ugo.oliviero@unina.it

¹ Department of Translational Medical Sciences, University Federico II, Via Pansini, 5, 80131 Naples, Italy

² ARCA (Associazioni Regionali Cardiologi Ambulatoriali), Campania, Italy

³ AMD (Associazione Medici Diabetologi), Campania, Italy

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.